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Background. Atherosclerotic vascular disease is a leading
cause of morbidity and mortality in patients with end-stage
renal disease (ESRD) on maintenance hemodialysis (HD).
Transforming growth factor-b1 (TGF-b1) is a multifunctional
cytokine that inhibits the atheromatous process. We studied
coding region polymorphisms of the TGF-b1 gene (+869 T → C
at codon 10 and +915 G → C at codon 25) as genetic susceptibil-
ity factors for prevalent vascular disease and cardiac outcomes
in a cohort of HD patients enrolled in the HEMO Study.
Methods. Genotyping was carried out using polymerase chain
reaction-sequence specific primer (PCR-SSP) methods with a
cytokine genotyping tray. Prevalent vascular disease was coded
from the Index of Disease Severity (IDS) scores for ischemic
heart disease (IHD), peripheral vascular disease (PVD), cere-
brovascular disease (CVD), and congestive heart failure (CHF),
0 indicating absence, and 1 to 3 increasing grades of severity.
The presence of any vascular disease (VD) (i.e., any degree of
IHD/PVD/CVD), and the number of coexistent vascular system
diseases per patient were derived. Cardiac outcomes, one of the
secondary outcomes of the HEMO Study, were expressed as a
composite of the first hospitalization for, or death from, cardiac
causes.
Results. The cohort consisted of 183 patients at enrollment,
56% male, 44% African American (AA), and 40% diabetic. The
mean age was 62.4 ± 12.2 years, and median dialysis vintage
2.02 years. The most frequent genotype at codon 10 was T/C
(67%), and at codon 25 was G/G (72%). IHD was present in
52% of patients; 65% had at least one vascular system involve-
ment, and 31% had 2 or more. On both univariate and multi-
variate analysis, the G/C genotype at codon 25 was significantly
associated with the presence and extent of vascular disease at
enrollment. The median time to cardiac outcome, defined as a
composite of the first hospitalization for, or death from, cardiac
causes, was 411 days in patients with the G/C genotype com-
pared with 851 days in those with the G/G genotype (P = 0.03).
Patients with the G/C genotype had a 1.6-fold increased hazard
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for cardiac outcomes after adjustment for baseline covariates
(P = 0.04).
Conclusion. The G/C substitution at codon 25 was associated
with an increased risk for prevalent vascular disease, new onset
cardiac morbidity, and cardiac mortality in HD patients, and
may be a genetic susceptibility factor for the development of
atherosclerosis. Further studies are required to evaluate the role
of TGF-b1 as a candidate gene.
Atherosclerotic vascular disease represents a signifi-
cant cause of morbidity and mortality in patients with
end-stage renal disease (ESRD). It is approximately 10
to 30 times more prevalent in patients treated by dialysis
compared with patients in the general population, after
stratification for gender, race, and the presence of dia-
betes mellitus [1]. Among incident hemodialysis (HD)
patients, approximately 40% have a history of ischemic
heart disease (IHD) and congestive heart failure (CHF)
[1, 2]. The high incidence of vascular complications in
these patients also involves peripheral vascular disease
and stroke, which are thought to be related to acceler-
ated atherogenesis [3, 4].
No combination of traditional risk factors has pro-
vided a convincing explanation for this high prevalence
of atherosclerotic vascular disease. Atherosclerosis is a
slowly progressive, inflammatory, proliferative process in
which various cellular elements such as macrophages,
smooth muscle, and endothelial cells are involved. In
recent years, experimental evidence has suggested that
TGF-b1 plays a key regulatory role in atherogenesis by
inhibiting both migration and proliferation of vascular
smooth muscle cells and macrophages, and by protecting
endothelial function [5, 6]. These in vitro observations
have been confirmed by several clinical studies indicating
a cardioprotective effect for high serum levels of TGF-b1,
both in the general population [7] and in HD patients [8].
It has also been shown that a high proportion of the circu-
lating concentration of TGF-b1 is under genetic control
[9]. Thus, polymorphisms involving the TGF-b1 gene may
provide a genetic susceptibility factor for atherosclerotic
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vascular disease. This study was undertaken to study the
association between single nucleotide polymorphisms at
the TGF-b1 locus (+869 T → C at codon 10 and +915
G → C at codon 25) and the prevalence of atherosclerotic
vascular disease and cardiac outcomes on follow-up, in-
cluding new onset cardiac hospitalization events and car-
diac death events, in a chronic hemodialysis population.
METHODS
Subjects
The study cohort consisted of 217 patients with ESRD
on maintenance HD recruited to the baseline phase of the
Hemodialysis (HEMO) Study from two Boston centers.
The HEMO Study was sponsored by the U.S. National In-
stitute of Diabetes, Digestive, and Kidney Diseases, and
the full-scale trial began in 1995. Details regarding the
design of the HEMO Study have been published else-
where [10]. In brief, this was a multicenter, prospective,
randomized clinical trial designed to evaluate the effect
of dialyzer urea and b 2-microglobulin clearances on the
morbidity and mortality of patients. Patients were eligible
for inclusion into the HEMO Study if they were between
the ages of 18 and 80 years, had been receiving chronic
hemodialysis three times per week, and had residual renal
urea clearance of less than 1.5 mL/min/35 L of urea dis-
tribution volume. Those patients in acute or chronic care
hospitals with active malignancy, decompensated cardiac,
hepatic, or pulmonary disease, serum albumin <3.0 g/dL,
interdialytic urea clearance >1.5 mL/min, pregnancy, or
a scheduled or recently (<6 months) failed transplant,
were excluded.
Blood samples for genotyping were available for 187
patients. Of these, 102 patients were Caucasian and 81
were African American. Because there were only four
patients representing other races, analysis of character-
istics at enrollment was confined to these 183 patients.
Randomization to either a standard or high dose of dial-
ysis, and to either a low or high flux dialyzer was carried
out in 176 patients in whom cardiac outcomes on follow-
up were studied. This ancillary study was approved by the
Human Investigation Review Committee, and all partic-
ipants provided written, informed consent.
Data procurement
Vascular disease definition at baseline. Demographic,
medical, and socioeconomic information was obtained
once patients were enrolled into the baseline phase of
the study. During the fifth week of the study, while the
patients were still in the baseline phase, their comorbid
medical conditions were assessed and recorded on a stan-
dardized form. The form was completed at each clinical
center by specially trained study coordinators. Comor-
bidity measures used in this study were obtained from
the Index of Disease Severity (IDS) scores used in com-
puting the Index of Coexistent Disease (ICED), a cod-
ing system that classifies the presence and severity of
19 different diseases and 11 physical impairments [11].
The information available for completion of the form in-
cluded chart progress notes, list of current medications,
the most recent laboratory data, chest x-ray report, elec-
trocardiogram, and hospital discharge summary. This as-
sessment was supplemented by interviews of the patients,
family members, primary nephrologists, and dialysis staff,
as necessary, to provide an assessment of the presence
and severity of disease. The present analysis focused upon
those scores related to vascular disease—namely, conges-
tive heart failure (CHF), ischemic heart disease (IHD),
peripheral vascular disease (PVD), and cerebrovascular
disease (CVD) scores. A score of ‘0’ indicated that the
condition was absent; ‘1’ indicated presence of the con-
dition with little or no morbidity, ‘2’ was symptomatic,
active disease requiring active treatment, but controlled
by treatment, and ‘3’ signified moderate to severe man-
ifestations despite treatment. Two composite variables
were derived: (1) aVD, defined by the presence of any
grade of IHD, PVD, or CVD; and (2) nVD, defined by
the total number of coexistent vascular diseases, and rep-
resenting the extent of atherosclerotic vascular disease in
the individual patient. This variable was expressed as a
numerical score of 0 to 3.
Cardiac outcomes during follow-up. Cardiac out-
comes were one of the secondary outcomes defined in
the HEMO Study. Time to a composite of the first hospi-
talization for cardiac causes or death from cardiac causes
was used as the end point for analysis. Cardiac death re-
ferred to deaths caused by IHD, CHF, arrhythmias, or
other heart disease. Thus, this composite outcome repre-
sented new onset cardiac hospitalization events, as well
as cardiac death events.
Laboratory data
Blood samples were obtained predialysis as part of
the routine clinical protocol within one month of enroll-
ment for measurement of routine laboratory parameters
(including serum total cholesterol and albumin). In ad-
dition, a 30 mL heparinized blood sample was also col-
lected as part of the ancillary study. Isolated peripheral
blood mononuclear cells (PBMC) aliquots were utilized
for DNA extraction and genotyping for the present study.
PBMC isolation and DNA extraction. PBMC were
harvested from whole blood as previously described using
Ficoll-Hypaque density gradient separation technique
[12]. Cells (2.5 × 106 PBMC/mL) were resuspended in
RPMI-1640 cell culture medium supplemented with L-
glutamine, NaHCO3, HEPES, penicillin, and strepto-
mycin and stored at −80◦C until DNA extraction.
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Genomic DNA was extracted using a spin column
method (QIAamp DNA Mini Kit, Qiagen, Valencia, CA,
USA). In brief, 2.5 × 106 PBMC were treated with 20 lL
of proteinase K (Qiagen), followed by the addition of
200 lL of sodium dodecyl sulfate to lyse the cells.
The homogeneous solution was incubated at 56◦C for
10 minutes, and 200 lL of 100% ethanol was added to
precipitate DNA. The mixture was then applied to the QI-
Aamp spin column, and after two washes with 500 lL of
wash buffer, genomic DNA was eluted by the addition of
200 lL of elution buffer. Final DNA concentrations were
50 to 200 ng/mL, determined by mini-gel electrophoresis.
TGF-b1 genotyping. The PCR-SSP approach was
used to analyze single nucleotide polymorphisms in the
coding regions of TGF-b1. The studied polymorphisms
were +869, Leu10 → Pro (T→C) at codon 10, and +915,
Arg25 → Pro (G→C) at codon 25. The genotypes in-
cluded T/T, T/C, and C/C at codon 10 and G/G, G/C, and
C/C at codon 25, respectively. PCR was performed on the
purified DNA using a Cytokine Genotyping Tray (One
Lambda, Inc., Canoga Park, CA, USA), which provided
sequence-specific oligonucleotide primers. In brief, 20 lL
of genomic DNA solution was added to D-mix, which
contains the dNTPs and reaction buffer, for the cytokine
genotyping. Taq polymerase (1.1 lL; Gibco BRL, Grand-
land, NY, USA) was then added to the D-mix, vortexed
for 15 seconds, and 10 lL of the D-mix mixture trans-
ferred to a 96-well microtiter genotyping tray with dried
primers in each reaction well. A Perkin-Elmer 9600 ther-
mocycler (Perkin-Elmer-Cetus, Norwalk, CT, USA) was
used to amplify the promoter regions by PCR. Samples
were subjected to 10 cycles at 96◦C for 10 seconds, and
63◦C for 60 seconds, followed by 20 cycles at 96◦C for
10 seconds, annealing temperature of 59◦C for 50 sec-
onds, and 72◦C for 30 seconds. After the PCR process, the
amplified DNA fragments were separated by agarose gel
electrophoresis and visualized by staining with ethidium
bromide and exposure to ultraviolet light in an UV tran-
silluminator. Interpretation of PCR-SSP results is based
on the presence or absence of a specific amplified DNA
fragment. An internal control primer pair was included
in every PCR reaction to exclude nonspecific amplifica-
tion affected by several factors, such as pipetting errors,
poor DNA quality, and presence of inhibitors. A posi-
tive reaction for a specific cytokine allele or allele group
is visualized on the gel as an amplified DNA fragment
between the internal control product band and the unin-
corporated primer band.
Statistical analysis
Analysis was performed using SAS software, version
8.2 (Cary, NC, USA). Data were expressed as mean and
standard deviation for continuous variables, and propor-
tions for categorical data.
Vascular disease at enrollment was represented by the
following individual outcome variables: CHF, each cat-
egory of vascular disease (IHD, PVD, CVD), the pres-
ence of any type of vascular disease as a composite
variable (aVD), and number of coexistent vascular dis-
eases (nVD). All except the last were coded dichoto-
mously (0 = absent, 1 = present), and logistic regression
models were used for univariate and multivariate
analyses.
The nVD was used as an ordinal outcome with 3 cat-
egories (0, 1, and ≥2). Proportional odds models were
constructed to derive the risk of having a greater number
of coexistent vascular diseases (i.e., a worse outcome, at-
tributable to a particular codon 10 or codon 25 genotype,
for univariate and multivariate analyses). The Mantel-
Haenszel test was used to compare the proportions of
patients with one or more coexistent vascular comorbidi-
ties (i.e., nVD scores 0, 1, 2, or 3) in the different genotype
categories to provide the chi-square estimate for a linear
trend (Epi Info 2000, version 1.1.2, Centers for Disease
Control and Prevention, Atlanta, GA, USA).
The odds ratios (and 95% confidence intervals) for
each outcome were computed in univariate models for
the following independent variables: age, gender, race,
duration on HD, serum albumin, serum total cholesterol,
diabetes, smoking history (categorized as nonsmokers
vs. current or past smokers), and codon 10 and codon
25 genotypes. Multivariate analyses were carried out by
a process of backward elimination of variables, forcing
the codon 10 and codon 25 genotypes into the models, to
evaluate their association with vascular disease. Covari-
ates included the traditional risk factors for cardiovas-
cular disease: age, gender, race, serum total cholesterol,
diabetes, and smoking history. Hypertension was not in-
cluded as a risk factor because it was a near universal
complication in this cohort. Results of serum cholesterol
were unavailable for approximately 15% of the cohort,
so the statistical technique of multiple imputations for
missing values was employed in the multivariate models.
However, as initial exploration showed no significant re-
lationship between serum cholesterol and outcome, it was
excluded from the final models. Serum albumin, again,
was not included in the final multivariable model as a co-
variate, as it is closely linked to pre-existing comorbidity,
and is not established as a predisposing risk factor for
vascular disease.
Time to a composite of the first hospitalization for car-
diac causes or death from cardiac causes was used as the
end point for survival analysis. Kaplan-Meier survival
curves for time to first cardiac hospitalization or death
from cardiac causes, stratified by genotype, were con-
structed. The log-rank statistic was used to test survival
time differences between genotypes. Cox proportional
hazard regression was used to adjust the relationship be-
tween genotypes and outcomes for baseline covariates
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Table 1. Patient and treatment characteristics
Age years 62 (12)
Male gender % 46
Race %
Caucasian 56
African American 44
Diabetes mellitus % 40
Dialysis vintage years 3.7 (4.4)
Primary kidney disease N (%)
Diabetic nephropathy 58 (32)
Hypertensive nephrosclerosis 58 (32)
Glomerular disease 25 (13)
Other 42 (23)
ICED score N (%)
1 60 (34)
2 58 (32)
3 60 (34)
Serum total cholesterol mg/dL 174 (41)
Serum albumin g/dL 3.6 (0.4)
Hematocrit % 33.4 (5.1)
Equilibrated Kt/V 1.4 (0.2)
Treatment groups (randomization)
Kt/V: Standard 90 (51)
High 86 (49)
Flux: Low 91 (52)
High 85 (48)
Data are displayed as mean (SD) or percentage.
as outlined above. Dialysis dose and flux grouping
assignment from the randomization of the parent study,
and the presence of baseline vascular disease derived
from the IDS scores, were included in multivariate Cox
models, in addition to baseline covariates. Hypertension,
serum cholesterol, and serum albumin were excluded
from the analysis based on the same rationale discussed
above. Here again, multivariate analysis was carried out
by a process of backward elimination of variables, forcing
the codon 10 and codon 25 genotypes into the models. The
proportional hazards assumption was met, both globally
for the model, and for individual variables in the model.
Because this was a study consisting of prevalent pa-
tients, and the outcome, vascular disease, has a relation-
ship to longevity, models were constructed both including
and excluding age, and interactions between genotypes
and age were explored as appropriate for each model.
RESULTS
The study population consisted of 183 patients enrolled
into the baseline phase of the HEMO Study. Baseline de-
mographic and clinical data are summarized in Table 1,
and the distribution of ICED scores and vascular comor-
bidities in Table 2. About two thirds of the cohort had
clinical evidence of IHD, PVD, or CVD, and approxi-
mately one half had a history of CHF. Hypertension was
present in 96% (176/183) of the cohort. Only 3% did not
receive recombinant erythropoietin therapy. Randomiza-
tion to either a standard or high dose of dialysis, and
to either a low or high flux dialyzer, was carried out in
176 patients of the original cohort, and therefore, out-
come data were available in these subjects.
Table 2. Vascular disease scoring in the study population
Score
0 1 2 3
Individual variable (IDS scores)a
CHF 85 (48) 63 (35) 23 (13) 7 (4)
IHD 85 (48) 24 (13) 65 (37) 4 (2)
PVD 123 (69) 18 (10) 29 916) 8 (5)
CVD 143 (80) 10 (6) 24 (13) 1 (1)
Composite variables
aVDb 63 (35) 115 (65)
nVDc 63 (35) 60 (34) 42 (24) 13 (7)
Abbreviations are: CHF, congestive heart failure; IHD, ischemic heart disease;
PVD, peripheral vascular disease; CVD, cerebrovascular disease; aVD, any vas-
cular disease; nVD, total number of coexistent vascular diseases. Values represent
number of patients (%). Complete data were available in 178 patients.
aScoring system represents the IDS scores for vascular disease.
bScoring system represents absence (score = 0) or presence (score = 1) of any
vascular disease.
cScoring system represents the total number of coexistent vascular diseases.
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Fig. 1. Distribution of codon 10 and codon 25 genotypes in the cohort.
Genotype distribution
Figure 1 shows the distribution of the TGF-b1 coding
region genotypes for the entire cohort. The T/C genotype
(heterozygous state) at codon 10 (118/183, 67%) and the
homozygous G/G genotype at codon 25 (140/183, 72%)
were the most frequent genotypes. There were no pa-
tients who were homozygous for the G→C substitution
at codon 25 (i.e., the C/C genotype). This provided three
genotype categories for codon 10 and two for codon 25.
The T/C-G/G combination was the most frequent (82/183,
44%) in the cohort.
Patient characteristics differed significantly by geno-
type and race, and hence, these demographic variables
were entered into multivariable models to adjust for con-
founding effects. Patients with the G/C genotype at codon
25 were significantly older (67 ± 8 vs. 61 ± 13 years; P =
0.002), and had higher serum total cholesterol (185 ± 40
vs. 167 ± 41 mg/dL; P = 0.02) compared to those with the
G/G genotype. The codon 25 G/C genotype was also as-
sociated with female gender (G/C vs. G/G: 65% vs. 51%;
P = 0.04), and marginally with Caucasian race (G/C vs.
G/G: 65% vs. 52%; P = 0.09). The distribution of diabet-
ics and smokers did not differ by genotype. No specific
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Table 3. Univariate analysis of the relationship between individual vascular comorbidities and TGF-b1 genotypes as well as other clinical
variables
IHD CVD PVD CHF
Predictor OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
G/C codon 25 (vs. G/G) 1.36 (0.71–2.62) 2.15 (1.00–4.63) 2.63 (1.33–5.18) 2.14 (1.10–4.19)
Age (per year increase) 1.05 (1.02–1.08) 1.04 (1.00–1.07) 1.05 (1.01–1.08) 1.06 (1.03–1.09)
Male gender (vs. female) 1.22 (0.68–2.21) 0.58 (0.27–1.24) 1.27 (0.67–2.41) 0.85 (0.47–1.53)
Caucasian race (vs. African American) 1.23 (0.68–2.23) 2.33 (1.04–5.21) 3.28 (1.63–6.63) 1.35 (0.75–2.44)
Diabetic (vs. nondiabetic) 2.87 (1.53–5.39) 1.01 (0.47–2.14) 1.12 (0.59–2.14) 1.93 (1.05–3.56)
Smoker (vs. nonsmoker) 1.19 (0.66–2.13) 0.70 (0.33–1.47) 1.52 (0.80–2.94) 0.90 (0.50–1.64)
Albumin (per g/dL increase) 0.62 (0.28–1.38) 0.82 (0.31–2.20) 0.77 (0.33–1.81) 0.45 (0.20–1.00)
Total cholesterol (per mg/dL increase) 1.00 (1.00–1.01) 1.00 (0.99–1.01) 1.00 (1.00–1.01) 1.01 (1.00–1.01)
Abbreviations are: IHD, ischemic heart disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; CHF, congestive heart failure. 95% CI, 95%
confidence interval for the odds ratio (OR). Codon 10 genotypes (T/C vs. T/T, or C/C vs. T/T) did not show a significant association with above outcomes.
Table 4. Factors associated with the presence of any vascular disease (aVD)
Univariate analysis Multivariate analysis
Variablea P value OR (95% CI) P value OR (95% CI)
G/C Codon 25 (vs. G/G) <0.01 3.05 (1.40–6.62) 0.045 2.51 (1.08–5.79)
Age (per year older) <0.01 1.06 (1.03–1.09) 0.01 1.04 (1.01–1.07)
Diabetic (vs. nondiabetic) <0.01 3.04 (1.53–6.03) <0.01 3.08 (1.48–6.44)
Caucasian race (vs. African American) 0.03 2.02 (1.08–3.76) 0.04 2.04 (1.02–4.07)
Male gender (vs. female) 0.60 0.85 (0.46–1.57)
Smoker (vs. nonsmoker) 0.46 1.22 (0.71–2.08)
Total cholesterol (per mg/dL increase)b 0.11 1.01 (1.00–1.02)
Serum albumin (per g/L increase)b 0.04 0.39 (0.16–0.95)
The final multivariable model was obtained by backward elimination of variables. 95% CI, 95% confidence interval for the odds ratio (OR).
aCodon 10 genotypes (T/C vs. T/T, or C/C vs. T/T) did not show a significant association to vascular disease.
bVariables not included in selection.
associations with demographic or clinical variables were
noted for codon 10 genotypes. Caucasian subjects were
older (64.2 ± 12.9 vs. 60.1 ± 11.0, P = 0.03), and a lower
proportion was female (41% vs. 70%, P < 0.01). The pro-
portion of diabetics did not differ by race.
Association between TGF-b1 genotypes and vascular
disease at enrollment
The G/C genotype at codon 25 was associated with
higher odds for the presence of CHF, PVD, and CVD,
although not for IHD. Older age was significantly associ-
ated with each individual outcome. IHD and CHF were
more prevalent in those with diabetes, and PVD and CVD
more prevalent in Caucasians. Codon 10 substitutions did
not show a significant relationship to any of the individual
vascular outcomes.
The G/C genotype at codon 25 was associated with a
three-fold increase in the odds for aVD on univariate
analysis. The final model after backward elimination of
variables is shown in Table 4. The G/C genotype at codon
25 provided a 2.3-fold greater risk (95% CI 1.02–5.3; P =
0.045) for the presence of vascular disease. Older age,
diabetes, and Caucasian race were the other significant
variables in the model. There was no association between
aVD and gender or smoking history.
Patients with the G/C genotype were significantly older
as compared to those with the G/G genotype. Because
both older age and the presence of the G/C genotype were
associated with higher odds for aVD, the effect of the G/C
genotype in different categories of age was explored. In
patients younger than 60 years, 92% (11/12) of those with
the G/C genotype had aVD, compared to 78% (31/40) in
patients aged 60 years or older. Respective proportions
for the G/G genotype were 40% in patients younger than
60 years, and 70% in patients aged 60 years or older. The
odds of vascular disease in relation to the G/C genotype
were significantly higher in younger patients (P = 0.02
for homogeneity of the odds ratios).
The G/C genotype was also associated with a higher
nVD score (P = 0.004, Mantel-Haenszel chi-square for
linear trend) (Fig. 2). The proportional-odds model con-
structed to identify factors associated with a higher
number of coexistent vascular diseases as an ordinal out-
come (nVD score) showed that the GC genotype was
associated with a 2.4-fold increase in odds for a higher
nVD score (95% CI 1.32–4.44; P = 0.004). The final mul-
tivariable model showed older age, diabetes, and Cau-
casian race to be the other significant variables associated
with a higher nVD score; their inclusion in the model di-
minished the strength of association between the G/C
genotype and the nVD score (Table 5). Figure 3 shows
the log-odds of a higher nVD score from the codon
25 genotypes as a function of increasing age, race, and
the age-codon 25 interaction, which was significant (P =
0.04) in this model.
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Fig. 2. Association between codon 25 genotypes and number of con-
comitant vascular comorbidity (ischemic heart disease, peripheral vas-
cular disease, and cerebrovascular disease) (Mantel-Haenszel chi-
square test for linear trend).
There was no demonstrable relationship between
codon 10 substitutions and either of the composite out-
comes representing prevalence and extent of vascular dis-
ease at baseline, in this cohort.
Association between TGF-b1 genotypes and cardiac
outcomes during follow-up
The median duration of follow-up was 825 days (1 to
2376 days). During the follow-up period there were 80
patients [45% with a first cardiac hospitalization event,
and 39 (22%) with a cardiac death event; a total of 91 pa-
tients (52%) had a composite event of either first cardiac
hospitalization or cardiac death. The median follow-up
to the composite event was 450 days (1 to 2376 days).
Kaplan-Meier analysis demonstrated (Fig. 4) that pa-
tients with the G/C genotype had a higher risk for the
first cardiac hospitalization or cardiac death compared
to patients with the G/G genotype (log-rank, P = 0.02).
Median time to event was 851 days in patients with the
G/G genotype, and 411 days in those with the G/C geno-
type. In univariate analysis, the G/C genotype was asso-
ciated with a HR of 1.6 for the outcome compared to the
G/G genotype (95% CI 1.06–2.51; P = 0.03). Multivariate
models were constructed using backward elimination of
variables, with and without the inclusion of age, as age
appeared to confound the effect of genotype on the out-
come (Table 6). Significant predictors of the outcome be-
sides codon 25 genotype and older age were, Caucasian
race, a history of smoking, and assignment to the low-
flux dialyzer limb of the study. Dialysis dose assignment,
gender, diabetes, and the presence of vascular disease at
enrollment did not enter the models.
The role of codon 25 genotypes was also explored in
diabetics versus nondiabetics, given that diabetes was a
strong risk factor for vascular disease at enrollment, but
not for new onset cardiac events or death. There were
35 (50.7%) events in diabetics and 56 (52.3%) events in
nondiabetics (P = 0.8). In the subgroup of diabetics, the
G/C genotype at codon 25 had no relationship to cardiac
outcomes, but assignment to the high-flux dialyzer limb of
the study had a HR of 0.48 (95% CI 0.23–0.98; P = 0.04),
and Caucasian race a HR of 2.10 (95% CI 1.05–4.18; P =
0.04). On the other hand, in nondiabetic patients, the
G/C genotype at codon 25 was a significant risk factor for
cardiac outcomes on follow-up (HR = 1.96, 95% CI 1.13–
3.42; P = 0.02) in addition to the presence of pre-existing
vascular disease at enrollment (HR = 2.66, 95% CI 1.45–
4.88; P < 0.01).
There was no demonstrable relationship between
codon 10 genotypes and time to the composite event of
first cardiac hospitalization or cardiac death in this cohort.
DISCUSSION
The present study assessed the relationship between
single nucleotide polymorphisms at the TGF-b1 locus
and atherosclerotic vascular disease in a cohort of main-
tenance hemodialysis patients. Prevalence of vascular co-
morbidity was established at the point of enrollment into
the HEMO Study using a previously validated scoring
system [11]. Composite outcome variables derived from
individual IDS scores for IHD, PVD, and CVD provided
additional sensitive markers for the presence, and ex-
tent of, pre-existing atherosclerotic vascular disease. Sec-
ondary outcomes defined in the HEMO Study included
a composite of first cardiac hospitalization events and
cardiac death events, allowing an estimate of new onset
cardiac events, as well as death resulting from IHD, CHF,
and other heart disease. These were the study end points
on follow-up used in the analysis. There was a significant
association between the G/C genotype at codon 25 and
the presence and extent of pre-existing vascular disease;
the associations with PVD and CVD individually were
also significant. In addition, patients with the G/C geno-
type showed a higher risk of developing new onset cardiac
hospitalization events or cardiac death on follow-up.
TGF-b1 is a member of a family of dimeric polypep-
tide growth factors that influences cellular proliferation
and differentiation and the production of extracellular
matrix. Experimental evidence shows that TGF-b1 in-
hibits migration and proliferation of smooth muscle cells,
endothelial cells, and macrophages, and may play a pro-
tective role against atherosclerosis [13–16]. Experimen-
tal inhibition of TGF-b1 signaling by either antibody to
TGF-b1 [17], or TGF-b1 receptor fusion protein that acts
as a competitive inhibitor of TGF-b1 binding [18], trans-
formed atherosclerotic plaques in ApoE null mice to an
inflammatory and unstable phenotype. Low serum levels
of TGF-b1 have been reported in some studies of human
atherosclerotic disease, both in patients without renal
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Table 5. Factors associated with a higher number of concomitant vascular diseases (nVD)
Univariate analysis Multivariate analysis
Variablea P value OR (95% CI) P value OR (95% CI)
G/C codon 25 (vs. G/G) 0.004 2.42 (1.32–4.44) 0.07 1.78 (0.95–3.36)
Age (per year older) 0.003 2.79 (1.42–5.47) <0.01 1.04 (1.02–1.07)
Caucasian race (vs. African American) 0.003 2.35 (1.35–4.11) <0.01 2.30 (1.28–4.13)
Diabetes mellitus (vs. nondiabetic) 0.01 2.03 (1.16–3.54) 0.02 2.00 (1.11–3.58)
Male gender (vs. female) 0.79 1.08 (0.63–1.85)
Smoker (vs. nonsmoker) 0.34 1.30 (0.76–2.22)
Total Cholesterol (per mg/dL increase)b 0.34 1.00 (0.99–1.01)
Serum albumin (per g/L increase)b 0.12 0.56 (0.27–1.15)
The final multivariable model was obtained by backward elimination of variables. 95% CI, 95% confidence interval for the odds ratio (OR).
aCodon 10 genotypes (T/C vs. T/T, or C/C vs. T/T) did not show a significant association with a higher number of concomitant vascular system diseases.
bVariables not included in selection.
insufficiency [7] and in ESRD patients [8], but not in oth-
ers [19–21].
An association between allelic polymorphisms in the
coding region of the TGF-b1 gene and the atheroma-
tous process may be related to the effect of the geno-
type on TGF-b1 production, genotypes associated with
lower TGF-b1 production, providing a higher elevated
risk. However, because allelic substitutions may poten-
tially influence any step between transcription to activa-
tion of TGF-b1 [22], the relationship between TGF-b1
genotypes and putative function may be more complex.
Grainger et al [9] recently showed that circulating lev-
els of TGF-b1 were under genetic control. In a study of
heart transplant recipients, Aziz et al [23] showed that
the codon 25 G/G genotype was associated with plasma
levels about one and half times higher than the G/C geno-
type. Awad et al [24] showed in lung transplant patients
that the G/G genotype at codon 25 was associated with
higher production of TGF-b1 by stimulated peripheral
blood mononuclear cells (PBMC) than the G/C geno-
type. An association between the G/C genotype at codon
25 and coronary artery disease was seen in the Etude
Cas-Temoin de l’Infarctus du Myocarde (ECTIM) Study,
which enrolled a non-ESRD population [22], but other
studies [25] have not demonstrated this association.
We believe that our results are especially significant,
given that we were able to demonstrate an association in
a prevalent hemodialysis population consisting of older
subjects. Although the G/C genotype was associated with
an elevated risk for vascular disease, both pre-existing
and new, it is noteworthy that patients with the G/C geno-
type were significantly older. Thus, models that adjusted
for age attenuated the effects of the codon 25 genotype
on vascular disease outcomes. The high case fatality rate
of vascular disease implies that we were already encoun-
tering a survival bias in this cohort, and it is conceivable
that many patients with the G/C genotype and vascular
disease succumbed before reaching ESRD. This is sup-
ported by our observations that in subjects <60 years
of age, over 90% of those with the G/C genotype had
pre-existing vascular disease, and that the risk for dis-
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Fig. 4. Kaplan-Meier survival plot of time to composite outcome event
of first cardiac hospitalization and cardiac death, by codon 25 genotypes
(log-rank P = 0.03).
ease accorded by the G/C genotype differed with age,
being higher in younger patients. Furthermore, the asso-
ciation of the risk factor (codon 25 GC genotype) with
incident events (cardiac hospitalization or cardiac death)
on prospective follow-up clarifies the presence of this
association. It is also significant that there was a total
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Table 6. Cox proportional hazards model of factors associated with the composite event of first cardiac hospitalization and cardiac death
Multivariate analysis
Univariate analysis Model excluding age Model including age
P value HR (95% CI) P value HR (95% CI) P value HR (95% CI)
Codon 25 (G/C vs. G/G) 0.03 1.63 (1.06–2.51) 0.04 1.56 (1.01–2.41) 0.12 1.42 (0.91–2.20)
Age (linear) 0.01 1.03 (1.01–1.05) 0.02 1.03 (1.00–1.05)
Caucasian race 0.001 2.15 (1.38–3.34) <0.01 2.10 (1.34–3.29) <0.01 1.98 (1.26–3.13)
Smoking 0.10 1.43 (0.94–2.17) 0.01 1.73 (1.12–2.66) <0.01 1.78 (1.16–2.75)
Flux group (high vs. low) 0.02 0.61 (0.40–0.94) 0.05 0.65 (0.42–0.99) 0.03 0.62 (0.40–0.95)
Kt/V group (high vs. standard) 0.47 1.16 (0.77–1.75)
Female gender 0.19 0.76 (0.50–1.15)
DM 0.25 0.78 (0.51–1.19)
Vascular disease at enrollment 0.04 1.63 (1.03–2.58)
Total Cholesterol (per mg/dL increase)a 0.82 1.00 (0.99–1.01)
Serum albumin (per g/L increase)a 0.89 1.05 (0.59–1.84)
The final multivariable model was obtained by backward elimination of variables.
aVariables not included in selection.
absence of the C/C genotype in this cohort. Although the
C/C genotype is infrequent—0.7% in the ECTIM Study
in a population without renal insufficiency [22], and 3%
in the study by Stefoni et al [8] in a Caucasian ESRD
cohort—it may be speculated that a heightened risk for
vascular disease from one or more copies of the C-allelle
at this locus compromises survival to ESRD and dialysis.
Although diabetes was strongly associated with pre-
existing vascular disease in this cohort, it did not predict
cardiac events or death on follow-up. However, subgroup
analysis by the presence of diabetes showed that the G/C
genotype tended to associate with cardiac outcomes in
nondiabetics, but not in diabetics. It can be argued that in
the absence of risk factors such as older age and diabetes,
specific genetic polymorphisms such as the G/C genotype
at codon 25 become important modulators of the risk of
vascular disease.
We were also able to demonstrate in this cohort that
assignment to high-flux dialyzers significantly decreased
the likelihood of adverse cardiac outcomes on follow-
up. Indeed, observations from secondary analyses of the
HEMO Study indicated a reduction in all cause mortal-
ity in patients dialyzing >3.7 years [26, 27], as well as a
reduction in specific cardiac related events [28].
We found no significant association between codon
10 genotypes and vascular disease outcomes, although
Yokota et al [20] noted a lower risk of IHD with the C/C
genotype compared to either the T/T or T/C genotypes.
Suthanthiran et al [29] found that the T/C and C/C geno-
types at codon 10 were more common in African Ameri-
can population groups who also hyperexpressed TGF-b1.
This is especially significant, as the present study found
Caucasian race to be a consistent risk factor for vascular
disease outcomes. We were, however, unable to demon-
strate any variation in codon 10 or codon 25 genotype
frequency by race.
We appreciate that this study is a secondary analysis on
a preselected cohort of patients enrolled in the HEMO
Study, and this may limit the generalizability of our infer-
ences. However, such a cohort provided us the advantage
of a relatively homogenous study population. Further,
as ESRD patients manifest accelerated atherosclerosis
[1], the previous probability for vascular disease as an
outcome was likely to be higher than in study popula-
tions without renal insufficiency, where similar associa-
tions have been addressed [20, 22, 25, 30]. Serum levels
of TGF-b1 were unavailable, and this limited our ability
to describe the phenotype more fully.
CONCLUSION
The relationship between TGF-b1 genotypes and
atherosclerotic vascular disease is complex, especially in
the context of CKD, and needs further study. There are
competing effects of this cytokine on fibrogenesis, vascu-
lar smooth muscle cell, and macrophage function, as well
as extracellular matrix production, in different target tis-
sues. In addition, interactions with demographic factors,
type and severity of kidney disease, clinical variables, and
physiologic pathways such as the renin-angiotensin sys-
tem would have a bearing on patient outcomes. Our study
has demonstrated that coding region polymorphisms in
the TGF-b1 gene are associated with both pre-existing
atherosclerotic vascular disease, and new onset cardiac
hospitalization events and cardiac death. Thus, TGF-b1
may be a candidate gene for atherosclerosis, a major cause
of morbidity and mortality in ESRD. The role of these ge-
netic factors need to be better defined because this would
allow for superior risk profiling of the individual patient,
and therefore, lead to more informed and targeted deci-
sions regarding therapy.
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